Since GIST is a rare disease, with an estimated incidence of about 0.0004% (4.2 cases per million people per year), as reported in a recent study [28], only large, prospective multicenter studies will be able to reliably assess the impact of specific KIT variants on long‐term outcomes. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.